Modus Therapeutics Holding AB (MODTX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.552x

Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has a cash flow conversion efficiency ratio of -0.552x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.00 Million ≈ $-538.40K USD) by net assets (Skr9.07 Million ≈ $976.18K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MODTX defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Modus Therapeutics Holding AB - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Modus Therapeutics Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Modus Therapeutics Holding AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Modus Therapeutics Holding AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Equity Story Group Ltd
AU:EQS
0.833x
Imunon Inc
NASDAQ:IMNN
-1.186x
Iron Road Ltd
AU:IRD
-0.021x
Nrgene Technologies Ltd
TA:NRGN
0.392x
Orient Press Limited
NSE:ORIENTLTD
0.114x
Dnonce Tech Bhd
KLSE:7114
0.031x
Patkol Public Company Limited
BK:PK
-0.022x
Dynasty Gold Corp
V:DYG
0.010x

Annual Cash Flow Conversion Efficiency for Modus Therapeutics Holding AB (2018–2025)

The table below shows the annual cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Modus Therapeutics Holding AB (MODTX) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr9.07 Million
≈ $976.18K
Skr-18.07 Million
≈ $-1.95 Million
-1.993x +71.00%
2024-12-31 Skr2.14 Million
≈ $229.98K
Skr-14.68 Million
≈ $-1.58 Million
-6.870x -628.09%
2023-12-31 Skr17.68 Million
≈ $1.90 Million
Skr-16.68 Million
≈ $-1.80 Million
-0.944x -111.23%
2022-12-31 Skr-2.58 Million
≈ $-278.19K
Skr-21.72 Million
≈ $-2.34 Million
8.404x +922.46%
2021-12-31 Skr15.73 Million
≈ $1.69 Million
Skr-16.08 Million
≈ $-1.73 Million
-1.022x +1.16%
2020-12-31 Skr7.00 Million
≈ $752.77K
Skr-7.23 Million
≈ $-778.17K
-1.034x -106.33%
2019-12-31 Skr-2.69 Million
≈ $-289.06K
Skr-43.90 Million
≈ $-4.72 Million
16.343x +1075.08%
2018-12-31 Skr23.90 Million
≈ $2.57 Million
Skr-40.06 Million
≈ $-4.31 Million
-1.676x --

About Modus Therapeutics Holding AB

ST:MODTX Sweden Biotechnology
Market Cap
$7.64 Million
Skr71.01 Million SEK
Market Cap Rank
#27679 Global
#615 in Sweden
Share Price
Skr0.40
Change (1 day)
-0.49%
52-Week Range
Skr0.27 - Skr3.83
All Time High
Skr6.80
About

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more